Wedge Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Wedge Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.2M	Sell	68,885 -758	-1%	-$36.4K	0.05%	256
2026 Q1	$3.6M	Sell	69,643 -8,452	-11%	-$430K	0.07%	237
2025 Q4	$3.88M	Buy	78,095 +8,514	+12%	+$414K	0.07%	242
2025 Q3	$3.33M	Sell	69,581 -4,319	-6%	-$174K	0.06%	259
2025 Q2	$2.33M	Buy	73,900 +6,614	+10%	+$212K	0.04%	301
2025 Q1	$2.2M	Buy	67,286 +13,955	+26%	+$494K	0.04%	304
2024 Q4	$1.93M	Buy	+53,331	New	+$1.88M	0.03%	335

Other funds holding SUPN

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CNAM

Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

JIR

James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wedge Capital Management's SUPN Position: Q2 2026 in Review

Wedge Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 1.1% in Q2 2026, selling an estimated $36.4K and leaving 68,885 shares worth $3.2M. The position accounts for 0.05% of the portfolio, ranked #256.

Wedge Capital Management first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.88M in Q4 2025. 58 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Wedge Capital Management held 68,885 shares of Supernus Pharmaceuticals worth $3.2M as of Q2 2026.
Wedge Capital Management sold 758 Supernus Pharmaceuticals shares in Q2 2026, an estimated $36.4K.
Supernus Pharmaceuticals made up 0.05% of Wedge Capital Management's portfolio in Q2 2026, its #256 holding.
Wedge Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Wedge Capital Management's Supernus Pharmaceuticals position peaked at $3.88M in Q4 2025.
58 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.